RxDoctor Payments Data

Shannon Schmidt

Hematology & Oncology · Appleton, WINPI 1033351465

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Pfizer. That places this record below the midpoint for hematology & oncology clinicians in WI, where the typical reported total is $411.

$102in general payments, 2019–2025

Across 1 payment — averaging $101.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$102
$144,628in research payments, 2019–2025

Across 5 payments — averaging $28,926 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$124K
  • Pfizer$20K
  • Merck$138

What the payments were for

  • Food & beverage$102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$102

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$102 in reported general payments places this provider in the 25th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$194,918
Medicare patients
212
Services billed
2,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib14$249,944
OrserduElacestrant Hcl11$242,175
EliquisApixaban41$27,925
Anastrozole268$4,610
Exemestane22$2,299
Tamoxifen Citrate79$1,319
Duloxetine Hcl43$1,168
Ondansetron Hcl42$773
Prochlorperazine Maleate39$711
Letrozole31$322
Dexamethasone14$273
Oxycodone Hcl23$224
Potassium Chloride17$150
Gabapentin11$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$27,92541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 248 hematology & oncology providers in Wisconsin.

Other hematology & oncology in Appleton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →